Detalles de la búsqueda
1.
A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis.
N Engl J Med
; 388(20): 1853-1862, 2023 May 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-37195941
2.
Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study.
Ann Rheum Dis
; 76(8): 1340-1347, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28130206
3.
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.
Ann Rheum Dis
; 76(1): 88-95, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-27689735
4.
Safety and efficacy of baricitinib at 24â weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.
Ann Rheum Dis
; 74(2): 333-40, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25431052
5.
Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial.
Ann Rheum Dis
; 72(3): 337-44, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22589376
6.
Real-world evidence on methotrexate-free subcutaneous tocilizumab therapy in patients with rheumatoid arthritis: 24-week data from the SIMPACT study.
Rheumatol Adv Pract
; 6(2): rkac038, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35663154
7.
Evaluation of response to 13-valent conjugated pneumococcal vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a phase 2 open-label extension study.
RMD Open
; 8(1)2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35246470
8.
Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial.
Lancet Rheumatol
; 4(6): e395-e406, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38293957
9.
Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2.
Rheumatol Ther
; 8(4): 1827-1844, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34661885
10.
Correction to: Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis.
Clin Rheumatol
; 39(11): 3527, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32965602
11.
Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis.
Clin Rheumatol
; 39(11): 3341-3352, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32876780
12.
A Comparative Study to Assess the Efficacy, Safety, and Immunogenicity of YLB113 and the Etanercept Reference Product for the Treatment of Patients with Rheumatoid Arthritis.
Rheumatol Ther
; 7(1): 149-163, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-31833011
13.
Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.
RMD Open
; 4(1): e000662, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29765703
14.
The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis.
Arthritis Rheumatol
; 68(9): 2163-73, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27059799
15.
The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study.
Arthritis Rheumatol
; 67(10): 2591-600, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26138593
Resultados
1 -
15
de 15
1
Próxima >
>>